Medical innovation is moving toward a future where “solid” bacteria are used not just as supplements, but as targeted medicines. A new biotech spin-off, aMylla, is leading this charge by focusing on the potential of lactobacilli to transform women’s healthcare. By leveraging these living bacteria, researchers aim to create sustainable alternatives to antibiotics for treating vaginal and urogenital conditions.
The venture is a collaborative effort between the University of Antwerp (UAntwerpen) and KU Leuven. The primary goal of the company is to develop medications that function broadly against various pathogens, addressing a critical gap in the treatment of female-specific health issues where traditional antibiotics are increasingly failing due to antimicrobial resistance.
Lactobacilli are key players in maintaining a healthy vaginal environment. According to Sarah Lebeer, a professor at the Department of Bio-Engineering at UAntwerpen, these beneficial bacteria help preserve harmful microbes under control and provide essential support to the immune system. While probiotics are widely available as dietary supplements, there has been a significant lack of clinical studies to prove their effectiveness as formal medicinal treatments.
The emergence of aMylla represents a shift from treating the microbiome as a general wellness concern to treating it as a precise therapeutic target. By focusing on the underlying mechanisms of the microbiome, the team aims to move beyond the “supplement” label and integrate living bacteria into formal medical treatment protocols.
Addressing the Crisis of Antibiotic Resistance in Women’s Health
The urgency behind this innovation is driven by the growing global threat of antibiotic resistance. In the context of urogenital health, the over-reliance on antibiotics can often lead to a cycle of recurrence, as these drugs may kill both the harmful pathogens and the beneficial bacteria that naturally protect the vaginal flora.
By using “good” bacteria as a medicine, aMylla seeks to provide a more sustainable approach. Rather than simply eradicating bacteria, these therapies aim to restore the natural balance of the microbiome, thereby inhibiting the growth of pathogens more naturally and effectively. This approach could potentially reduce the need for repeated courses of antibiotics and mitigate the risk of developing resistant strains.
The researchers have already begun contributing to the scientific understanding of these processes. Professor Lebeer and her colleagues have published a review in the journal Cell Host & Microbe, highlighting the need for a deeper understanding of the mechanisms within the microbiome to develop more effective treatments for vaginal and urogenital disorders .
The Role of Lactobacilli as a ‘Gamechanger’
Lactobacilli are not new to medicine, but their application as a prescription-grade drug is a significant evolution. In a healthy vaginal environment, these bacteria produce lactic acid, which maintains a low pH and creates a hostile environment for many pathogens. They also interact with the host’s immune system to signal the presence of threats and coordinate a defense.
The biotech company is focusing on two primary areas of healthcare: respiratory diseases and women’s health. While the broader application of living bacteria as medicine is being explored, the specific focus on the vaginal microbiome is intended to provide a “boost” to female healthcare, which has historically received less research attention than other areas of medicine.
The transition from laboratory research to clinical application is the primary hurdle. Most current probiotic treatments are marketed as supplements, which means they do not undergo the same rigorous clinical trial process as pharmaceuticals. AMylla intends to bridge this gap by conducting the necessary clinical studies to ensure these bacterial therapies are safe, effective, and suitable for inclusion in official medical treatment schemes.
Key Takeaways for Patients and Providers
- New Therapeutic Approach: aMylla is developing “living medicines” using lactobacilli to treat urogenital and respiratory conditions.
- Combatting Resistance: The goal is to provide a sustainable alternative to antibiotics, reducing the impact of antimicrobial resistance.
- Academic Roots: The company is a spin-off from UAntwerpen and KU Leuven, based on research published in Cell Host & Microbe.
- Beyond Supplements: The focus is on moving probiotics from the realm of dietary supplements into clinically validated medical treatments.
- Immune Support: Lactobacilli are used because they naturally support the immune system and keep harmful microbes in check.
What So for the Future of Biotechnology
The work being done by aMylla is part of a larger trend in biotechnology known as “live biotherapeutic products.” This involves the use of live organisms—such as bacteria, yeast, or fungi—to prevent, treat, or cure a disease. By focusing on the specific niches of the human body, such as the vaginal or respiratory tracts, scientists can create highly localized treatments that have fewer systemic side effects than traditional oral antibiotics.
For the global medical community, this represents a shift toward personalized and ecological medicine. Instead of a “one size fits all” antibiotic, the future may involve restoring a patient’s specific microbial balance to allow the body to heal itself. What we have is particularly vital for chronic conditions where the microbiome has been severely disrupted.
As aMylla progresses, the focus will remain on the translation of laboratory insights into bedside treatments. The ability to identify specific “promising molecules” and mechanisms within the lactobacilli populations will allow for the development of targeted therapies that can be tailored to the specific type of infection or imbalance a patient is experiencing.
The next phase for the spin-off will involve the continued development of these innovative therapies and the pursuit of the clinical data required to move these “good” bacteria into formal healthcare settings. Updates on clinical trial progress and regulatory filings will be the key markers for the success of these therapies in the coming years.
Do you think living bacteria could replace antibiotics for common infections? We invite you to share your thoughts and experiences in the comments below.